Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22897322 | 0.82 | DPP4 (0.69) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL22897332 | 0.80 | DPP4 (0.67) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL22897334 | 0.76 | DPP4 (0.61) | DPP4 | |
| SCHEMBL1911524 | 0.73 | DPP4 (0.55) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL4502814 | 0.72 | CCR1 (0.65) | DPP4 | |
| SCHEMBL22897331 | 0.71 | DPP4 (0.60) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL21253578 | 0.70 | P2RX7 (0.70) | DPP4DPP8DPP9P2RX7 | |
| SCHEMBL22897326 | 0.70 | DPP4 (0.55) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL22897330 | 0.69 | DPP4 (0.61) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL5747070 | 0.69 | HPGD (0.61) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894794-B1 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as antidiabetics | KING ABDULAZIZ UNIVERSITY (SA) | 2021-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894794-B1 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as antidiabetics | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 4/4885DPP9 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.